Report

The intracranial aneurysm market is expected to register a CAGR of 4.5% during the forecast period.

The COVID-19 pandemic severely impacted the market for intracranial aneurysms by directly affecting demand and production, disrupting the supply chain, and increasing the financial burden on firms. Brain surgeries were postponed or even canceled during this timeframe to reduce the spread of the virus. In worst-affected nations, such as the United States, Russia, India, Brazil, France, the United Kingdom, Italy, and Spain, neurosurgical operations fell by 55%. However, according to a study published in January of the base year titled "COVID-19 and Hospital: A review," up to 36% of hospitalized COVID-19 patients experienced neurological symptoms, and there were several ischemic and hemorrhagic infarctions. These findings suggested COVID-19 may enhance sales in the neurology industry. Thus, these factors created lucrative opportunities for the market to grow shortly, providing profitable opportunities for key players post-COVID-19.

The increasing number of patients suffering from high blood pressure and trauma to blood vessels is another factor driving the market for intracranial aneurysms. Hypertension significantly increases the risk of a brain aneurysm and other diseases. A large percentage of the population is at risk of developing brain aneurysms due to high blood pressure and smoking. As per the WHO updates from the base year, an estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, with most (two-thirds) living in low- and middle-income countries. It is estimated that this trend will continue to rise even in the forecast period and lead to intracranial aneurysms. Thus, the market is expected to experience substantial growth in the future. In addition, the global population is aging at an accelerating pace.

Moreover, according to a study published in October of the base year titled "Unruptured Cerebral Aneurysms in Elderly Patients: Key Challenges and Management," the prevalence of unruptured brain aneurysms in elderly patients was rapidly increasing in patients aged 70 years or older. According to the World Population Prospects, this year, the share of the global population aged 65 years or above is projected to rise from 10% to 16% in 2050. By 2050, the number of people aged 65 years or over worldwide is projected to be more than twice the number of children under age five and about the same as that of children under age 12. Therefore, with the increase in the elderly population, intracranial aneurysms are expected to increase. The market is expected to show better growth over the forecast period.

The increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive the market's growth. For instance, in June this year, India Medtronic launched Conformite Europeenne (CE) marked fourth-generation flow diverter, Pipeline Vantage with Shield Technology, for endovascular treatment of brain aneurysms. Moreover, in February 2022, Viz.ai software received United States Food and Drug Administration clearance for automatically spotting brain aneurysms. Such factors potentially drive the demand to adopt intracranial aneurysm treatments worldwide.

However, the high cost of treatment is expected to hamper the growth of the intracranial aneurysm market.

Intracranial Aneurysm Market Trends

Endovascular Coiling Segment is Expected to Hold a Significant Share in the Intracranial Aneurysm Market

Endovascular coiling is estimated to witness healthy growth in the future. It is a minimally invasive technique wherein a catheter is used to treat the brain aneurysm by preventing blood from getting into arteries. Benefits associated with this procedure, such as easy access to the vertebrobasilar system, multiple aneurysms in distant areas, and shorter recovery time compared to other procedures, propelling the segment's growth.

In addition, the growing number of strokes worldwide has a high chance of rupturing blood vessels and leading to intracranial aneurysms, thus promoting revenue growth in the market.

For instance, according to data published by World Stroke Organization (WSO) in 2022, About 12 million (12,224,551) people experienced a stroke. The organization stated that there are more than 12.2 million new strokes each year, and globally, one in four people after 25 years of age experience a stroke in their lifetime. Hence, the increasing burden of patients with stroke globally is expected to drive the market's growth.

Moreover, increasing product launches by key players are expected to boost the market. For instance, in June 2022, Rapid Medical announced the expansion of its portfolio in the United States and the first Numen coil embolization procedure. Rapid Medical has an exclusive distribution agreement with MicroPort NeuroTech, a subsidiary of MicroPort Scientific Corporation. Thus, product launches are expected to boost the market segment's growth over the forecast period.

Thus, all factors mentioned above are expected to boost the segment over the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a significant market share in the intracranial aneurysm market due to the increasing aging population, increasing prevalence of intracranial aneurysms, rising demand for minimally invasive procedures, and incidences of hypertension and stroke.

Stroke is a condition where treatment must be given as early as possible after the onset of symptoms. Hence, the availability of quick treatment is a key factor responsible for the high survival rate in the United States. According to the statistics published by the CDC in April 2022, more than 795,000 Americans have strokes. Of this, 610,000 are found to be new cases each year. Statistics revealed stroke is one of the causes of death in the United States; every 40 seconds, people from the United States have a stroke. The increasing number of patients suffering from stroke is expected to increase the demand for its treatment, driving the market for intracranial aneurysms.

North America is expected to observe the same dominance during the forecast period due to the development of innovative therapies, major industry players' local presence, and new therapies' entry. In September 2022, Vesalio announced the Food and Drug Administration's approval of the NeVa VS to treat cerebral vasospasm after aneurysmal rupture.

Thus, all factors above are expected to boost the market over the forecast period.

Intracranial Aneurysm Market Competitor Analysis

The intracranial aneurysm market is moderately competitive and consists of several major players. Some companies currently dominating the market are Stryker, B. Braun Melsungen AG, MicroPort Scientific Corporation, Medtronic, Terumo Corporation, Integra LifeSciences Corporation, Johnson & Johnson, and RAUMEDIC AG.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support